Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
9.34
+0.57 (6.50%)
At close: Sep 26, 2025, 4:00 PM EDT
9.44
+0.10 (1.07%)
After-hours: Sep 26, 2025, 7:45 PM EDT
Rezolute Employees
Rezolute had 71 employees as of June 30, 2025. The number of employees increased by 12 or 20.34% compared to the previous year.
Employees
71
Change (1Y)
12
Growth (1Y)
20.34%
Revenue / Employee
n/a
Profits / Employee
-$1,048,056
Market Cap
848.18M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RZLT News
- 10 days ago - Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 11 days ago - Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug - Seeking Alpha
- 15 days ago - Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 25 days ago - Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism - GlobeNewsWire
- 4 weeks ago - Rezolute to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer - GlobeNewsWire
- 2 months ago - Rezolute to Participate in the BTIG Virtual Biotechnology Conference - GlobeNewsWire
- 2 months ago - Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) - GlobeNewsWire